aidsmap/nam, 25 October 2016
SImplification of an antiretroviral treatment to a boosted protease inhibitor and the nucleoside analogue lamivudine (a dual regimen) is highly effective in people switching from a stable three-drug regimen, researchers reported on Monday at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow).
Read more here
BMJ 2016; 352 doi: (Published 19 January 2016) What is already known on this topic Patients’ preferences are a hallmark of patient centered care, but little is known about how wording of offers of testing can influence perceived preferences Opt-in and opt-out HIV testing have not been compared in a randomized controlled setting US guidelines endorse opt-out HIV testing, and Europe has seen a...
NAM , 02 December 2015 The results from the Ipergay study of intermittent pre-exposure prophylaxis (PrEP) were published in the New England Journal of Medicine (NEJM) on 1 December, World AIDS Day. The journal-published results are little changed from those presented at the CROI conference last February by principal investigator Jean-Michel Molina, but the researchers make a number of additional...